Here are three things to know:
1. The strategic partnership for the nonexclusive worldwide distribution of the mesenchymal cells will allow BI-USA to bring full cell culture solutions to its customers.
2. StemExpress uses proprietary technology to readily expanded BM-MSCs from healthy donors.
3. StemExpress, BI-USA and partner labs have evaluated the performance of StemExpress Human BM-MSCs in combination with BI-USA’s NutriStem MSC Medium. Itdemonstrated improved MSC expansion compared to industry-standard MSC culture conditions.
More articles on biologics:
Burst Biologics’ umbilical cord blood-derived product is a promising option for spinal fusion, study finds
Orthobiologics market to reach $10.1B by 2025 — 6 key market players
Regenerative medicine company names Susan Vogt to board of directors: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
